Literature DB >> 26123761

The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.

Kenichi Yoshida1, Hidenori Fukuoka2, Ryusaku Matsumoto1, Hironori Bando1, Kentaro Suda3, Hitoshi Nishizawa3, Genzo Iguchi3, Wataru Ogawa1, Susan M Webb4, Yutaka Takahashi1.   

Abstract

PURPOSE: To develop a Japanese version of the acromegaly quality of life (QoL) questionnaire (AcroQoL) and investigate the factors associated with impaired QoL in patients with acromegaly.
METHODS: We developed a Japanese version of the AcroQoL by a forward-backward method and evaluated QoL in 38 patients with acromegaly who had been followed up at an outpatient clinic at Kobe University Hospital. Its reliability was examined with Cronbach's alpha and item-total correlations. Second examination was performed for concurrent validity by assessment of correlations with the Short Form-36 (SF-36) and longitudinal analysis of the AcroQoL in 25 patients.
RESULTS: Cronbach's alpha and item-total correlations showed a range of 0.76-0.93 and 0.20-0.84, respectively, and significant correlations were found between the AcroQoL and the SF-36. Younger age and a history of radiotherapy were associated with worse total score by the multivariate linear regression analysis (p = 0.020 and p = 0.042, respectively). Intriguingly, in the biochemically-controlled group after the exclusion of patients who received radiotherapy, patients who underwent surgery alone exhibited a higher psychological (75.0 vs. 65.7 %, p = 0.036) and appearance (64.3 vs. 53.6 %, p = 0.036) score than those who are treating with pharmaceutical therapy.
CONCLUSIONS: The reliability of the Japanese version of the AcroQoL was satisfactory. Younger age and a history of radiotherapy were associated with lower QoL in patients with acromegaly. In biochemically-controlled acromegaly, patients who underwent surgery alone exhibited better QoL than those under pharmaceutical therapy.

Entities:  

Keywords:  Acromegaly; Japanese patients; Pharmaceutical therapy; Remission; Surgery

Mesh:

Year:  2015        PMID: 26123761     DOI: 10.1007/s11102-015-0665-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  46 in total

1.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

2.  Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly.

Authors:  Jitske Tiemensma; Adrian A Kaptein; Alberto M Pereira; Johannes W A Smit; Johannes A Romijn; Nienke R Biermasz
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

Review 3.  Health-related quality of life in pituitary diseases.

Authors:  Iris Crespo; Elena Valassi; Alicia Santos; Susan M Webb
Journal:  Endocrinol Metab Clin North Am       Date:  2014-11-04       Impact factor: 4.741

4.  The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Vincenzo Esposito; Antonio Santoro; Francesca Solda; Patrizia Gargiulo; Guido Tamburrano; Riccardo Maurizi Enrici
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

5.  Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.

Authors:  Shih-Che Hua; Yuan-Horng Yan; Tien-Chun Chang
Journal:  Eur J Endocrinol       Date:  2006-12       Impact factor: 6.664

6.  Radiotherapy for pituitary adenomas: long-term efficacy and toxicity.

Authors:  Sara C Erridge; David S Conkey; Diane Stockton; Mark W J Strachan; Patrick F X Statham; Ian R Whittle; Robin Grant; Gillian R Kerr; Anna Gregor
Journal:  Radiother Oncol       Date:  2009-11-10       Impact factor: 6.280

7.  Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.

Authors:  Maria P Matta; Elisabeth Couture; Laurent Cazals; Delphine Vezzosi; Antoine Bennet; Philippe Caron
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 8.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

9.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

Authors:  S J C M M Neggers; M O van Aken; W W de Herder; R A Feelders; J A M J L Janssen; X Badia; S M Webb; A J van der Lely
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

10.  Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.

Authors:  Agatha A van der Klaauw; Nienke R Biermasz; Hendrieke C Hoftijzer; Alberto M Pereira; Johannes A Romijn
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-01       Impact factor: 3.478

View more
  7 in total

1.  Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Authors:  Roberto Salvatori; Pietro Maffei; Susan M Webb; Thierry Brue; Jane Loftus; Srinivas Rao Valluri; Roy Gomez; Michael P Wajnrajch; Maria Fleseriu
Journal:  Pituitary       Date:  2022-01-12       Impact factor: 4.107

Review 2.  Cognitive-behavioral therapy improves the quality of life of patients with acromegaly.

Authors:  Lia Silvia Kunzler; Luciana Ansaneli Naves; Luiz Augusto Casulari
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 3.  Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters.

Authors:  Victor J Geraedts; Cornelie D Andela; Günter K Stalla; Alberto M Pereira; Wouter R van Furth; Caroline Sievers; Nienke R Biermasz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-03       Impact factor: 5.555

4.  Health-related Quality of Life in Acromegaly Patients: Results from Generic and Disease-specific Questionnaires.

Authors:  Bruno de A Oliveira; Bruna Araújo; Tainá M Dos Santos; Bárbara R Ongaratti; Carolina G S Leães Rech; Nelson P Ferreira; Júlia F S Pereira-Lima; Miriam da C Oliveira
Journal:  Indian J Endocrinol Metab       Date:  2020-11-09

5.  The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment.

Authors:  Naoki Yamamoto; Shin Urai; Hidenori Fukuoka; Masaaki Yamamoto; Kenichi Yoshida; Masaki Suzuki; Hiroki Shichi; Yasunori Fujita; Keitaro Kanie; Genzo Iguchi; Yutaka Takahashi; Wataru Ogawa
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-03       Impact factor: 5.555

6.  Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly.

Authors:  Laura E Dichtel; Allison Kimball; Kevin C J Yuen; Whitney Woodmansee; Melanie S Haines; Qiu Xia Guan; Brooke Swearingen; Lisa B Nachtigall; Nicholas A Tritos; Julie L Sharpless; Ursula B Kaiser; Anu V Gerweck; Karen K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2020-09-11       Impact factor: 3.523

7.  Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study).

Authors:  Muhammad Fahad Arshad; Oluwafunto Ogunleye; Richard Ross; Miguel Debono
Journal:  Pituitary       Date:  2021-05-12       Impact factor: 4.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.